戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 is (Mtb), as adjunctive treatment given with antitubercular drugs.
2 AGP is also regarded as a target for several antitubercular drugs.
3 otential to be developed into a new class of antitubercular drugs.
4 otential target to develop antibacterial and antitubercular drugs.
5 um tuberculosis and is the target of several antitubercular drugs.
6 rculosis (M. tb) emphasizes the need for new antitubercular drugs.
7 M/LM balance might represent targets for new antitubercular drugs.
8  the oxidative activation of other thioamide antitubercular drugs.
9 the development of a novel chemical class of antitubercular drugs.
10 Ps in five genes affecting the metabolism of antitubercular drugs.
11 rovide targets for development of innovative antitubercular drugs.
12 otential target for the development of novel antitubercular drugs.
13  be leveraged to develop new, more effective antitubercular drugs.
14 afish larvae for in vivo characterization of antitubercular drug activity and tolerance.
15 ates Pks13 as an attractive novel target for antitubercular drugs and supports development of alterna
16 ) has been shown to increase the efficacy of antitubercular drugs, and fusing macrophage-inflammatory
17 ation issues, including interactions between antitubercular drugs, antiretroviral drugs, and medicine
18 e originally been designed as hybrids of the antitubercular drugs BM212 (1) and SQ109 (2), which show
19            Rationale: Standardized dosing of antitubercular drugs contributes to a substantial incide
20 netics (PK) often represents a challenge for antitubercular drug development.
21   MbtA is a validated therapeutic target for antitubercular drug development.
22 dy tuberculosis pathogenesis, as well as for antitubercular drug discovery.
23 sect with its metabolism and be exploited in antitubercular drug discovery.
24                                     Standard antitubercular drugs exhibit various limitations like to
25 g pocket of Eis is a potential target of new antitubercular drugs expected to overcome aminoglycoside
26 acogenomic assays that predict metabolism of antitubercular drugs have been lacking.
27       The mechanisms of action of the unique antitubercular drugs, including isoniazid, ethambutol, a
28                 Isoniazid (INH), a frontline antitubercular drug, inhibits InhA, the enoyl reductase
29      One challenge to the development of new antitubercular drugs is the existence of multiple virule
30 erium marinum to thiacetazone, a second line antitubercular drug, is associated with a severe decreas
31 tuberculosis, is the target of the frontline antitubercular drug isoniazid (INH).
32                                The preferred antitubercular drug isoniazid specifically targets a lon
33 obacterium tuberculosis and a target for the antitubercular drug isoniazid.
34  clearance in mice during treatment with the antitubercular drug isoniazid.
35                              We examined the antitubercular drugs isoniazid, rifampicin, and moxiflox
36 ponsible for activation of the commonly used antitubercular drug, isoniazid (INH).
37 e for increased resistance to the front-line antitubercular drug, isoniazid, by acetylating and hence
38 losis, is important in the activation of the antitubercular drug, isoniazid.
39 sis is responsible for the activation of the antitubercular drug isonicotinic acid hydrazide (INH) an
40            Rationale: Standardized dosing of antitubercular drugs leads to variable plasma drug level
41                       In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bacte
42 at M. tuberculosis transports the first-line antitubercular drug rifampicin through a proton gradient
43  tuberculosis compared to the two first-line antitubercular drugs rifampicin and isoniazid.
44  study used Fischer 344 rats primed with the antitubercular drug, rifampicin, plus phenobarbitone, an
45 ween these two components was provided using antitubercular drugs such as ethambutol or isoniazid kno
46 nt enzymes, which hampers the development of antitubercular drugs targeting this pathway.
47 s is inhibited by isoniazid, a key frontline antitubercular drug that is inactivated by mycobacterial
48                              Bedaquiline, an antitubercular drug that targets ATP-synthase, is a key
49 osis highlights the need for identifying new antitubercular drugs that can treat these infections.
50 s the efficacy of ethionamide, a second-line antitubercular drug used to combat multidrug-resistant M
51                                 However, new antitubercular drugs with new mechanisms of action have
52 ly) TB; hence the quest for highly effective antitubercular drugs with novel modes of action is imper
53 ssociate binary resistance phenotypes for 15 antitubercular drugs with variants extracted from candid